

19th Annual Biosimilars Congregation 2024

#VIbsc

"Uniting market leaders to analyse advanced commercial developments
& to identify successful management strategies of Biosimilars"

11th December 2024, Hotel Kohinoor Continental, Mumbai, India

AGENDA AT A GLANCE

Key Speakers

Conference Info

Day One

Floor Plan

Booking Details

Key Speakers Include



SANJEEV GUPTA
Sr. Vice President & Head Biosimilar
Ipca Laboratories



MILIND ANTANI
Leader, Pharma and Healthcare
Nishith Desai Associates



SD SINHA
Senior VP, Development
Hetero Labs



PRITHWIJIT KUNDU
CMO - NCE, NDD
Wockhardt



ABIR BANERJEE
VP & Head R&D Biotech
Bharat Serums and Vaccines



PANKAJ THAKUR
GM, Clinical Project Management - Drug
Discovery, Biologics, Hetero Labs



SANTOSH TAUR
Director Medical Affairs, Vaccines, Rare
Diseases & Digital, Pfizer



DATTATRAY PAWAR
Head Medical Affairs - Deputy GM
Alkem Laboratories



MANNAN KHAMBATI
Assistant VP Biotech Manufacturing
Bharat Serums and Vaccines



SEEMA BHANDARKAR
Global Program Manager Biosimilar Operations
Biocon



SOURABH FULMALI
Global Medical Director
GSK



UMA SINHA DATTA
Director PDS India
Cytiva



SANCHIT NANDA
Senior Director, Global Patient Solutions
Gilead Sciences



SANJAY B. NIRANJAN
Assistant Director, Bioassay Development
(Biosimilars), Lupin



AMARNATH SUGUMARAN
Associate Director & Cluster Head Medical
Affairs, Cipla



MAYUR MAYBHATE
Head Medical Affairs
Alkem Laboratories



UDAY HARLE
Asst. VP/ Global Head Clinical Development
Kashiv BioSciences



ANURAG TIWARI
AVP, R&D
Zumutor Biologics



ABHISHEK SINHA
Global Director - Regulatory Affairs
Advanz Pharma



KAVITA LAMROR
Partner, RWE & Digital Transformation
Maxis Clinical Sciences



AKSHAYA ODAK
Head - Regulatory Affairs (Biotech)
Lupin



ROSHAN PAWAR
Head Medical Affairs
Alkem Laboratories

Conceptualised By



+91 44 42108101

info@virtueinsight.com

19th Annual Biosimilars Congregation 2024

#VIbsc

“Uniting market leaders to analyse advanced commercial developments
& to identify successful management strategies of Biosimilars”

11th December 2024, Hotel Kohinoor Continental, Mumbai, India

AGENDA AT A GLANCE

Key Speakers

Conference Info

Day One

Floor Plan

Booking Details

Key Speakers Include



SAMIR KULKARNI
Head - DBT ICT Center
Institute Of Chemical Technology



APARNA PRABHUNE
Asst GM Regulatory Affairs
Wockhardt



SWEETY MATHEW
Regulatory Professional- Global Regulatory
Affairs: CMC Rare Diseases, **Novo Nordisk**



KHOKAN DEBNATH
Sr GM / (Head) - Regulatory Affairs, Clinical
Operations, PV & QA (India & Emerging
Market), **Wockhardt**



RANJIT BARSHIKAR
CEO
QBD International, United Nations Adviser



VISHWAS SOVANI
Founder Director
Pharmawisdom



SHALU KASLIWAL
Group Lead - Medical Sciences, Biologics
Dr. Reddy's Laboratories

Plus More Coming Soon...

SUPPORTED BY



19th Annual Biosimilars Congregation 2024

#VIbsc

“Uniting market leaders to analyse advanced commercial developments
& to identify successful management strategies of Biosimilars”

11th December 2024, Hotel Kohinoor Continental, Mumbai, India

AGENDA AT A GLANCE

Key Speakers

Conference Info

Day One

Floor Plan

Booking Details

KEY THEMES DISCUSSED

- Integrated approach to biosimilar development & commercialization
- Current trends and strategies to access biosimilar market
- Innovative clinical approach in biosimilars & Clinical development of biosimilars
- Factors that drive the selection of a biosimilar asset
- Imperatives for R&D in biosimilars - Entering the next wave of growth
- Addressing developmental challenges to maximize biosimilars market growth
- Global Perspectives: Impact of Biosimilars around the world – What have we learned so far?
- Market Access - Implications for product launch and market exclusivity
- Commitment to Quality - Excellence in manufacturing biosimilars
- Overcoming Barriers to the Market Access of Biosimilars
- Who can influence payers on Biosimilar decision making
- What type of evidence will be needed for registering Biosimilars in the future?
- Outlining what investors wish inventors knew before coming to the table
- RWE - What type of evidence will be needed for registering Biosimilars in the future?
- Ensuring the balance between product development and patient safety
- Technology: Unlocking the better ways
- Regulatory - The evolving regulatory framework for biosimilar approvals
- What comes next for the biosimilars market?
- Be part of a major networking opportunity

WHO SHOULD ATTEND AND WHO YOU'LL MEET

CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:

- Biopharmaceuticals/ Biotherapeutics
- Follow on Biologics/Follow on Proteins
- Biologics/Biotechnology/ Bio generics
- Legal Affairs
- Intellectual Property
- Health Economics
- Pricing and Reimbursement
- Clinical Immunology
- Principal Scientist
- Chief Scientific Officer
- Process Control and Analytical Technologies
- Analytical Characterisation
- Regulatory
- Quality Affairs/ Quality Control
- New Product Development
- Process Science
- Portfolio Management
- Research & Development
- Business Development
- Business Operations
- Scientific Affairs
- Commercial Affairs



+91 44 42108101



info@virtueinsight.com

19th Annual Biosimilars Congregation 2024

#VIbsc

"Uniting market leaders to analyse advanced commercial developments
& to identify successful management strategies of Biosimilars"

11th December 2024, Hotel Kohinoor Continental, Mumbai, India

AGENDA AT A GLANCE

Key Speakers

Conference Info

Day One

Floor Plan

Booking Details

DAY ONE - 11th December 2024

08:30 – Coffee and registration – An opportunity to meet and to network with your conference colleagues.

CLINICAL DEVELOPMENT

09:30 – Keynote Address - Clinical development issues with Biosimilar development & update

SD SINHA
Senior VP, Development
Hetero Labs

TRENDS & STRATEGIES

10:00 – KEYNOTE PANEL DISCUSSION: Current trends and strategies to access biosimilar market

- Critical aspects of the global Biosimilar market such as vendor landscape, competitive strategies, market drivers and challenges
- Changing market dynamics within the Biosimilars market
- Innovative clinical approach in biosimilars & Clinical development of biosimilars
- Emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.
- Examining potential barriers to formulary inclusion and reimbursement, including payer preferences and rebate structures
- Current challenges in developing Biosimilars
- Factors that drive the selection of a biosimilar asset
- Identify how biosimilars have improved health equity and access to treatment for patients?
- What makes manufacturers to decide ultimately to bring or not a biosimilar to the market?

Moderator:

RANJIT BARSHIKAR
CEO
QBD International, United Nations Adviser

Panellists:

SANJEEV GUPTA
Sr. Vice President & Head Biosimilar
Ipca Laboratories

MANNAN KHAMBATI
Assistant VP Biotech Manufacturing
Bharat Serums and Vaccines

UDAY HARLE

Asst. VP/ Global Head Clinical Development
Kashiv BioSciences

ROSHAN PAWAR
Head Medical Affairs
Alkem Laboratories

SAMIR KULKARNI
Head - DBT ICT Center
Institute Of Chemical Technology

UMA SINHA DATTA
Director PDS India
Cytiva

11:00 – Morning Coffee / Tea & Discussion

R&D

11:30 – Imperatives for R&D in biosimilars - Entering the next wave of growth

- Analysing the current and future demand for biologics.
- Success rates for developing new biosimilars
- Global Perspectives: Impact of Biosimilars around the world – What have we learned so far?
- Monitor the biosimilars market landscape and prepare for change
- Interchangeability studies
- Strengthen the foundations by enhancing the R&D operating model

MANUFACTURING

12:00 – Addressing developmental challenges to maximize biosimilars market growth

- Challenges and obstacles faced by manufacturers in developing biosimilars
- How to overcome challenges, increase development success and optimize result
- 3 onerous hurdles - Manufacturing costs, complex reimbursement dynamics, and market. How to navigate to become and remain sustainable?
- Techniques in bringing the next generation of Biosimilars to the market
- Reducing capital investment and creating cost effective and scalable manufacturing operations

19th Annual Biosimilars Congregation 2024

#VIbsc

"Uniting market leaders to analyse advanced commercial developments
& to identify successful management strategies of Biosimilars"

11th December 2024, Hotel Kohinoor Continental, Mumbai, India

AGENDA AT A GLANCE

Key Speakers

Conference Info

Day One

Floor Plan

Booking Details

DAY ONE - 11th December 2024

- Assessing the competitive landscape and pricing pressures posed by originator biologic manufacturers
- Examining the influence of originator biologic manufacturers' incentive strategies such as bundling deals and loyalty programs, on biosimilar market dynamics

12:30 - Networking luncheon

REGULATORY

13:30 - KEYNOTE PANEL DISCUSSION: Regulatory - The evolving regulatory framework for biosimila approvals

- Regulatory Updates on Biosimilars
- Adapting to regulatory shifts in approval pathways and staying ahead of induced infringement
- Regulatory factors that go into determining a pathway to biosimilar development
- Prepare and adjust product development plans in light of the evolving regulatory landscape
- Regulatory environment for biosimilar and interchangeable development and licensure
- Interchangeability and switching biosimilar: Regulator's view
- Significance of multiple forces - regulatory, political, and commercial
- What's next? Ways to proceed forward

Moderator:

MILIND ANTANI
Leader, Pharma and Healthcare
Nishith Desai Associates

Panellists:

AKSHAYA ODAK
Head - Regulatory Affairs (Biotech)
Lupin

KHOKAN DEBNATH
Sr GM / (Head) - Regulatory Affairs, Clinical Operations, PV & QA (India & Emerging Market), Wockhardt

SWEETY MATHEW
Regulatory Professional- Global Regulatory Affairs: CMC Rare Diseases, Novo Nordisk

APARNA PRABHUNE
Asst GM Regulatory Affairs
Wockhardt

14:30 - Navigating through the regulatory complexities of biological molecules

- Complexity of biological molecules
- Regulatory framework for development of biological molecules
- Robust CMC package

SWEETY MATHEW

Regulatory Professional- Global Regulatory Affairs: CMC Rare Diseases, Novo Nordisk

15:00 - Afternoon Tea / Coffee

MARKET ACCESS

15:20 - Panel Discussion - Market Access - Implications for product launch and market exclusivity

- The Business of Biosimilars: Strategically exploring options for sustainability amidst hurdles faced by biosimilars market
- Understanding how product launches are influenced
- Ensuring pathways for innovative cures
- Identify best practices developed in foreign markets
- Discussing strategies for negotiating favorable access and reimbursement rates for biosimilars against originator biologics
- Who can influence payers on Biosimilar decision making
- Entry strategies, countermeasures to economic impact & marketing channels
- Key factors that impacting market and economic growth
- New product and existing product strategies to maintaining sustainability in biosimilars

Moderator:

VISHWAS SOVANI
Founder Director
Pharmawisdom

Panellists:

ABIR BANERJEE
VP & Head R&D Biotech
Bharat Serums and Vaccines

SANCHIT NANDA
Senior Director, Global Patient Solutions
Gilead Sciences

19th Annual Biosimilars Congregation 2024

“Uniting market leaders to analyse advanced commercial developments
& to identify successful management strategies of Biosimilars”

#VIbsc

11th December 2024, Hotel Kohinoor Continental, Mumbai, India

DAY ONE - 11th December 2024

AGENDA AT A GLANCE

Key Speakers
Conference Info
Day One
Floor Plan
Booking Details

SANJAY B. NIRANJAN

Assistant Director, Bioassay Development (Biosimilars)
Lupin

PANKAJ THAKUR

GM, Clinical Project Management - Drug Discovery,
Biologics, Hetero Labs

ANURAG TIWARI

AVP, R&D
Zumutor Biologics

SHALU KASLIWAL

Group Lead - Medical Sciences, Biologics
Dr. Reddy's Laboratories

SEEMA BHANDARKAR

Global Program Manager Biosimilar Operations
Biocon

RWE

16:10 - PANEL DISCUSSION: RWE - What type of evidence
will be needed for registering Biosimilars in the
future?

- Identify the tendencies and different perspectives on the evolution of data requirements for licensing of biosimilars
- Benefits of RWE for Biosimilars and special populations
- Designing & conducting RWE studies
- Real-world Data from multiple sources to conduct Biosimilar comparison studies
- Devise plans for implementation while leveraging perspectives from other markets
- Best practices & lessons learnt from past
- Penetrating the biosimilars marketplace - What comes next for the biosimilars market?

Moderator:

KAVITA LAMROR

Partner, RWE & Digital Transformation
Maxis Clinical Sciences

Panellists:

SANTOSH TAUR

Director Medical Affairs, Vaccines, Rare Diseases & Digital
Pfizer

SOURABH FULMALI

Global Medical Director
GSK

ABHISHEK SINHA

Global Director - Regulatory Affairs
Advanz Pharma

MAYUR MAYBHATE

Head Medical Affairs
Alkem Laboratories

PRITHWIJIT KUNDU

CMO - NCE, NDD
Wockhardt

AMARNATH SUGUMARAN

Associate Director & Cluster Head Medical Affairs
Cipla

DATTATRAY PAWAR

Head Medical Affairs - Deputy GM
Alkem Laboratories

17:00 - Closing remarks and end of conference

FOR SPONSORSHIP OPPORTUNITIES

Sponsorship or exhibition is the best way to speed network with decision makers. The world leader speakers in our conferences attract niche delegates from all over the world. This would be a wonderful opportunity to reach the right audience and save money and time on all your other advertising gimmicks. To give you an advertising edge we constantly update the industry pioneers via emails/news letter about the event and advertise the event via different forms of media.

Sponsorship Enquires - info@virtueinsight.com

FOR DELEGATE REGISTRATIONS

Our potent conference agenda delivering the latest information and the world class leaders as speakers attract delegates to attend from around the world. We aim for our attendees to be equipped with knowledge of latest developments & enable them to network with the industry key personnel.

Delegate Registration - bookings@virtueinsight.com

19th Annual Biosimilars Congregation 2024

#VIbsc

“Uniting market leaders to analyse advanced commercial developments
& to identify successful management strategies of Biosimilars”

11th December 2024, Hotel Kohinoor Continental, Mumbai, India

AGENDA AT A GLANCE

Key Speakers

Conference Info

Day One

Floor Plan

Booking Details

FLOOR PLAN - Book your stalls now before they run out !!!




Sold



Blocked



Vacant



(3x2 Mtr Stall)

1.

(3x2 Mtr Stall)

5.

(3x2 Mtr Stall)

9.

(3x2 Mtr Stall)

2.

(3x2 Mtr Space)

6.

(3x2 Mtr Stall)

10.

(3x2 Mtr Stall)

3.

(3x2 Mtr Stall)

7.

(3x2 Mtr Space)

11.

(3x2 Mtr Stall)

4.

(3x2 Mtr Stall)

8.

Note :- The floorplan is subject to change at the discretion of the organisers.

19th Annual Biosimilars Congregation 2024

#VIbsc

"Uniting market leaders to analyse advanced commercial developments
& to identify successful management strategies of Biosimilars"

11th December 2024, Hotel Kohinoor Continental, Mumbai, India

AGENDA AT A GLANCE

Key Speakers

Conference Info

Day One

Floor Plan

Booking Details

REGISTER ONLINE :

Link : <https://konfhub.com/virtue-insights-biosimilars-congregation-2024>

For Multiple Bookings - Photocopy this form and send it to : info@virtueinsight.com

REGISTRATION FORM

RESERVATION PRICING:

Super Early Bird Price (Valid Till 18th October 2024)

Cost per delegate - Fee: INR 11,000 + GST(18%)

Standard Price

Cost per delegate - Fee: INR 16,000 + GST(18%)

Please email us at bookings@virtueinsight.com

Registration Form Details:

Forename Surname.....

Job Title

Company

GST No (If Applicable)

Official Contact Number

Address

Country Postcode

Phone Fax

Email

I confirm that I have read & agree to the
terms and conditions of booking..... (Please Tick) ☐

Signature

Methods of Payments:

By Cheque - Complete and return the above registration form via
post or email, together with your cheque payable to Virtue Insight.

By Bank Transfer:

Account Name - Virtue Insight
Account Type - Current
Account Number - 915020031763553
Bank Name - Axis Bank
Bank Address - 2/8 LAMBERT NAGAR, 1st cross street,
Virugambakkam, Chennai - 600 092
Branch Name - Virugambakkam, Chennai
Swift Code - AXISINBB211
NEFT / IFSC Code - UTIB0000211
Micro Code - 600211010

Queries:

Should you have any questions on bookings,
Please feel free to contact us.

Email: info@virtueinsight.com
Web: <https://virtueinsight.com/>
India Office: Tel: +91 44 42108101
UK Office: Tel: +44-20 3509 3779

General Information Venue:

Kohinoor Continental Hotel
Andheri Kurla Road
Andheri (E)
Mumbai 400059 - India
Tel: 91 22 66919000 / 91 22 28209999

TERMS AND CONDITIONS:

Payment terms: Virtue Insight requires the full amount to be paid before
the conference. We may refuse entry to delegates who have not paid their
invoice in full.

Cancellations: Delegates and vendors are subject to the following charges
and refunds upon withdrawal or cancellation between 2-3 month's prior 75%
cancellation fee/ 25% refund. Less than 2 months prior to the event Full
cancellation fee / No refund.

Administration Fee: If you cancel your participation (once confirmed) and
haven't paid the attendance fee you will be liable to pay an
administration fee of INR 5,000

Substitutions/Name Change: If you are unable to attend you may nominate,
in writing, another delegate to take your place at any time prior to the start of
the event. This can be done at no extra cost.

Presentation: If you cannot attend the conference, you can still purchase the
presentations (Subject to availability) - Please email to
bookings@virtueinsight.com

Indemnity: Virtue Insight reserves the right to make alterations to the
conference/executive briefing content, timing, speakers or venue without
notice. The event may be postponed or cancelled due to unforeseen events
beyond the control of Virtue Insight. If such a situation arises, we will
reschedule the event.

Fee: The conference fee includes lunch, refreshments and conference papers
provided on the day. This fee does not include travel or hotel
accommodation.

Covid Situation, Natural Calamity, National Security: In the case where
the government decide to go into a lockdown or restrictions on social and
business gatherings during the dates of the conference, the event will be post-
poned to a new date. Registered clients can choose to join the conference on
the new date or decide to take a credit note for their payment so that they
can decide to participate for any of our future events within the time frame
of next one year.

VENUE

Kohinoor Continental Hotel

Address: Andheri Kurla Road,
Andheri (E),
Mumbai - 400059,
India.

CLICK
HERE
for more details

MAP & DIRECTIONS

Conceptualised By



+91 44 42108101

info@virtueinsight.com